BioNTech SE (BSP:B1NT34) Total Stockholders Equity : R$108,180 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is BioNTech SE Total Stockholders Equity?

BioNTech SE's Total Stockholders Equity for the quarter that ended in Dec. 2023 was R$108,180 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. BioNTech SE's Book Value per Share for the quarter that ended in Dec. 2023 was R$28.44. The ratio of a company's debt over equity can be used to measure how leveraged this company is. BioNTech SE's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.01.

BioNTech SE Total Stockholders Equity Historical Data

The historical data trend for BioNTech SE's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE Total Stockholders Equity Chart

BioNTech SE Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

2,250.60

8,585.77

75,997.38

111,440.30

108,179.78

BioNTech SE Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial															111,440.30	113,012.68	104,680.58	104,713.09	108,179.78

BioNTech SE (BSP:B1NT34) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

BioNTech SE's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(108179.783	-	0)	/	3803.61
	=	28.44

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

BioNTech SE's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(150.147	+	1020.569)	/	108179.783
	=	0.01

BioNTech SE Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of BioNTech SE's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

BioNTech SE (BSP:B1NT34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (BSP:B1NT34) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

BNTX:USA BNTX:Mexico 0A3M:UK 22UA:Germany BNTX:Austria

Address

An der Goldgrube 12, Mainz, RP, DEU, D-55131

Website

https://www.biontech.de

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.

BioNTech SE (BSP:B1NT34) Headlines

No Headlines